Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 57

Sort by

Sort Order Select

Journal Articles

Defining the Drivers of Idelalisib-Related Early Autoimmune Toxicity in Chronic Lymphocytic Leukemia

Saurabh Yadav, Suraj Singh, Binu Kandathilparambil Sasi, Mandovi Chatterjee, Victor Barrera, Shannan Ho Sui, Stacey M Fernandes, Samantha J. Shupe, John-Hanson Machado, Mano Joseph Mathew, Jennifer R. Brown

Blood (2023) 142 (Supplement 1): 6511.

https://doi.org/10.1182/blood-2023-186136

Published: 2023

Journal Articles

Investigating the Influence of Germline ATM Variants on Susceptibility to Chronic Lymphocytic Leukemia and Other Malignancies

Roberta Santos Azevedo, Francesca Morelli, Kiyomi Mashima, Rayan Fardoun, Svitlana Tyekucheva, Stacey M Fernandes, Samantha J. Shupe, Marissa Terra, Anisha Patel, Joseph Yu, Jennifer R. Brown

Blood (2023) 142 (Supplement 1): 3266.

https://doi.org/10.1182/blood-2023-180136

Published: 2023

Journal Articles

Understanding Resistance Mechanisms and Growth Kinetics of CLL Treated with Covalent and Non-Covalent BTK Inhibitors

Aishath Naeem, Liang Li, Filippo Utro, Justin Cha, Junko Tsuji, Stacey M Fernandes, Roberta Santos Azevedo, Francesca Morelli, Zunqiu Wang, Samantha J. Shupe, Kahn Rhrissorrakrai, Chaya Levovitz, Brian P Danysh, Alexandria Kluge, Matthew S Davids, Ignaty Leshchiner, Laxmi Parida, Gad Getz, Jennifer R. Brown

Blood (2023) 142 (Supplement 1): 4623.

https://doi.org/10.1182/blood-2023-186052

Published: 2023

Journal Articles

Characterizing ATM Aberrations in Chronic Lymphocytic Leukemia (CLL): Prognostic Implications and Sensitivity to PARP Inhibition

Kiyomi Mashima, Mariia Mikhaleva, Stacey M Fernandes, Samantha J. Shupe, Svitlana Tyekucheva, Matthew S. Davids, Jennifer R. Brown

Blood (2023) 142 (Supplement 1): 6507.

https://doi.org/10.1182/blood-2023-187406

Published: 2023

Journal Articles

Higher Mutational Burden Is an Independent Predictor of Shorter Time to First Treatment in Untreated Chronic Lymphocytic Leukemia Patients

Mariia Mikhaleva, Svitlana Tyekucheva, Kiyomi Mashima, Stacey M Fernandes, Matthew S Davids, Jennifer R. Brown

Blood (2023) 142 (Supplement 1): 3270.

https://doi.org/10.1182/blood-2023-173738

Published: 2023

Journal Articles

A Phase 2 Study of Acalabrutinib, Umbralisib, and Ublituximab (AU2) in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Inhye E Ahn, Yinglu Zhou, Svitlana Tyekucheva, Hannah Cormier, Stacey M Fernandes, Josie Montegaard, Marykate Kilcommons, Jennifer L Crombie, Reid W. Merryman, Erin M Parry, Philippe Armand, David C Fisher, Caron A Jacobson, Matthew S Davids, Jennifer R. Brown

Blood (2023) 142 (Supplement 1): 1914.

https://doi.org/10.1182/blood-2023-180788

Published: 2023

Journal Articles

Novel Pi3kδ Inhibitor Roginolisib Synergizes with the Bcl-2 Inhibitor Venetoclax in Hematological Malignancies

Binu Kandathilparambil Sasi, Chiara Tarantelli, Elisa Civanelli, Eleonora Cannas, Stacey M Fernandes, Samantha J. Shupe, Michael Lahn, Lars van der Veen, Giusy Di Conza, Francesco Bertoni, Jennifer R. Brown

Blood (2023) 142 (Supplement 1): 4179.

https://doi.org/10.1182/blood-2023-180073

Published: 2023

Journal Articles

Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samples

Blood (2023) 142 (5): 421–433.

https://doi.org/10.1182/blood.2022016600

Published: 2023

Includes: Supplemental data

Journal Articles

Prevalence of Clonal Hematopoiesis of Indeterminate Potential in Patients with Monoclonal B-Cell Lymphocytosis Compared to Untreated Chronic Lymphocytic Leukemia

Anisha V. Patel, Abirami Vijenthira, Aswin Sekar, Christopher J. Gibson, Stephen P. Martindale, Rayan Fardoun, Svitlana Tyekucheva, Stacey M. Fernandes, Binyamin A. Knisbacher, Cynthia K. Hahn, Gad Getz, Catherine J. Wu, Matthew S. Davids, Jennifer R. Brown

Blood (2022) 140 (Supplement 1): 7038–7040.

https://doi.org/10.1182/blood-2022-162707

Published: 2022

Journal Articles

Evolutionary History of Transformation from Chronic Lymphocytic Leukemia to Richter Syndrome

Blood (2022) 140 (Supplement 1): 1530–1533.

https://doi.org/10.1182/blood-2022-160335

Published: 2022

Journal Articles

Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Blood (2022) 140 (Supplement 1): 837–838.

https://doi.org/10.1182/blood-2022-168003

Published: 2022

Journal Articles

Characteristics of Rare Germline ATM Variants in Chronic Lymphocytic Leukemia (CLL)

Kiyomi Mashima, Benjamin L. Lampson, Aditi Gupta, Nicholas Moore, Anna Petrackova, Samantha J. Shupe, Stacey M. Fernandes, Amaro Taylor-Weiner, Riaz Gillani, Hoyin Chu, Seunghun Han, Sabrina Camp, Eric Kofman, Gad Getz, Catherine J. Wu, Eliezer Van Allen, Saud H AlDubayan, Jennifer R. Brown

Blood (2022) 140 (Supplement 1): 9853–9854.

https://doi.org/10.1182/blood-2022-167009

Published: 2022

Journal Articles

Integrating High-Throughput Dynamic BH3 Profiling and Molecular Phenotyping to Identify Therapeutic Vulnerabilities in CLL

Salma Parvin, Binyamin A. Knisbacher, Aditi Aryal, Stacey M. Fernandes, Donna S. Neuberg, Catherine J. Wu, Jennifer R. Brown, Gad Getz, Anthony G. Letai

Blood (2022) 140 (Supplement 1): 6983–6984.

https://doi.org/10.1182/blood-2022-169352

Published: 2022

Journal Articles

Resistance to the Non-Covalent BTK Inhibitor Pirtobrutinib

Blood (2022) 140 (Supplement 1): 6981–6982.

https://doi.org/10.1182/blood-2022-160279

Published: 2022

Journal Articles

Mechanistic Insights into Immune Related Toxicities in Subjects with Relapsed/ Refractory Follicular Lymphoma Treated with Zandelisib

Binu Kandathilparambil Sasi, Stephen P. Martindale, Samantha J. Shupe, Stacey M. Fernandes, Saurabh Yadav, John-Hanson Machado, Tycel Phillips, Andrew D. Zelenetz, Jennifer R. Brown

Blood (2022) 140 (Supplement 1): 3575–3576.

https://doi.org/10.1182/blood-2022-159167

Published: 2022

Journal Articles

Association of Clonal Hematopoiesis of Indeterminate Potential with Time to First Treatment, Incidence of Richter's Syndrome, and Overall Survival in Patients with Chronic Lymphocytic Leukemia

Abi Vijenthira, Aswin Sekar, Christopher J. Gibson, Stephen P. Martindale, Rayan Fardoun, Svitlana Tyekucheva, Yue Ren, Stacey M. Fernandes, Binyamin A. Knisbacher, Cynthia K. Hahn, Gad Getz, Catherine J. Wu, Matthew S. Davids, Jennifer R. Brown

Blood (2022) 140 (Supplement 1): 9868–9870.

https://doi.org/10.1182/blood-2022-163273

Published: 2022

Journal Articles

METTL3 Dysregulates RNA Splicing by Translational Control of Splicing Factors via m 6 A Modification in CLL

Yiming Wu, Meiling Jin, Mike Fernandez, Kevyn Hart, Aijun Liao, Stacey M. Fernandes, Tinisha McDonald, Lucy Ghoda, Daniel Roeth, Markus Kalkum, Raju Pillai, Jianjun Chen, Jennifer R Brown, Alexey V. Danilov, Steven T. Rosen, Tanya Siddiqi, Lili Wang

Blood (2021) 138 (Supplement 1): 499.

https://doi.org/10.1182/blood-2021-149691

Published: 2021

Journal Articles

Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia

Ishwarya Murali, Siddha Kasar, Aishath Naeem, Svitlana Tyekucheva, Jasneet K. Khalsa, Emily M. Thrash, Gilad Itchaki, Dimitri Livitz, Ignaty Leshchiner, Shuai Dong, Stacey M. Fernandes, Gad Getz, Amy Johnson, Jennifer R. Brown

Blood (2021) 138 (1): 44–56.

https://doi.org/10.1182/blood.2020006765

Published: 2021

Includes: Supplemental data

Journal Articles

miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors

Blood (2021) 137 (18): 2481–2494.

https://doi.org/10.1182/blood.2020005627

Published: 2021

Includes: Supplemental data

Journal Articles

Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL

Marco V. Haselager, Karoline Kielbassa, Johanna ter Burg, Danique J. C. Bax, Stacey M. Fernandes, Jannie Borst, Constantine Tam, Francesco Forconi, Giorgia Chiodin, Jennifer R. Brown, Julie Dubois, Arnon P. Kater, Eric Eldering

Blood (2020) 136 (25): 2918–2926.

https://doi.org/10.1182/blood.2019004326

Published: 2020

Includes: Supplemental data

NARROW

Defining the Drivers of Idelalisib-Related Early Autoimmune Toxicity in Chronic Lymphocytic Leukemia

Investigating the Influence of Germline ATM Variants on Susceptibility to Chronic Lymphocytic Leukemia and Other Malignancies

Understanding Resistance Mechanisms and Growth Kinetics of CLL Treated with Covalent and Non-Covalent BTK Inhibitors

Characterizing ATM Aberrations in Chronic Lymphocytic Leukemia (CLL): Prognostic Implications and Sensitivity to PARP Inhibition

Higher Mutational Burden Is an Independent Predictor of Shorter Time to First Treatment in Untreated Chronic Lymphocytic Leukemia Patients

A Phase 2 Study of Acalabrutinib, Umbralisib, and Ublituximab (AU2) in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Novel Pi3kδ Inhibitor Roginolisib Synergizes with the Bcl-2 Inhibitor Venetoclax in Hematological Malignancies

Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samples

Prevalence of Clonal Hematopoiesis of Indeterminate Potential in Patients with Monoclonal B-Cell Lymphocytosis Compared to Untreated Chronic Lymphocytic Leukemia

Evolutionary History of Transformation from Chronic Lymphocytic Leukemia to Richter Syndrome

Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Characteristics of Rare Germline ATM Variants in Chronic Lymphocytic Leukemia (CLL)

Integrating High-Throughput Dynamic BH3 Profiling and Molecular Phenotyping to Identify Therapeutic Vulnerabilities in CLL

Resistance to the Non-Covalent BTK Inhibitor Pirtobrutinib

Mechanistic Insights into Immune Related Toxicities in Subjects with Relapsed/ Refractory Follicular Lymphoma Treated with Zandelisib

Association of Clonal Hematopoiesis of Indeterminate Potential with Time to First Treatment, Incidence of Richter's Syndrome, and Overall Survival in Patients with Chronic Lymphocytic Leukemia

METTL3 Dysregulates RNA Splicing by Translational Control of Splicing Factors via m 6 A Modification in CLL

Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia

miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors

Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only